Table 1 Clinical characteristics (our secondary end-point) of headache and associated symptoms after cilostazol
From: Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
Sumatriptan (n = 30) | Placebo (n = 30) | p-value a | |
|---|---|---|---|
Number of participants reporting headache | 30 | 30 | 1.00 |
(range 1–10 on NRS) | |||
Median peak headache score (range) | 5 (1–10) | 7 (1–10) | 0.03b |
No. of participants with | |||
Unilateral location | 15 | 16 | 1.00 |
Throbbing headache | 19 | 21 | 0.63 |
Aggravation by physical activity | 26 | 27 | 1.00 |
Nausea | 17 (2c) | 17 (3c) | 1.00 |
Photophobia | 14 | 17 | 0.25 |
Phonophobia | 10 | 14 | 0.29 |
Rescue medication | 25 | 29 | 0.13 |
Migraine-like attack | 18 | 19 | 1.00 |